Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

ACS Medicinal Chemistry Letters

Volumn 9, Issue 4, 2018, Pages 300-305

  Popovici Muller, Janeta ^a,d   Lemieux, René M ^a,e   Artin, Erin ^a,e   Saunders, Jeffrey O ^a,f   Salituro, Francesco G ^a,g   Travins, Jeremy ^a,h   Cianchetta, Giovanni ^a   Cai, Zhenwei ^b   Zhou, Ding ^b,i   Cui, Dawei ^b   Chen, Ping ^b   Straley, Kimberly ^a,j   Tobin, Erica ^a,e   Wang, Fang ^a   David, Muriel D ^c   Penard Lacronique, Virginie ^c   Quivoron, Cyril ^c   Saada, Véronique ^c   De Botton, Stéphane ^c   Gross, Stefan ^a   Dang, Lenny ^a   Yang, Hua ^a   Utley, Luke ^a,k   Chen, Yue ^a   Kim, Hyeryun ^a   Jin, Shengfang ^a   Gu, Zhiwei ^b   Yao, Gui ^b   Luo, Zhiyong ^b   Lv, Xiaobing ^b   Fang, Cheng ^b   Yan, Liping ^b   Olaharski, Andrew ^a,l   Silverman, Lee ^a   Biller, Scott ^a   Su, Shin San M ^a,d   Yen, Katharine ^a   more..

^a AGIOS PHARMACEUTICALS   (United States)

^b PharmaResources ^*  (China)

^c Universite Paris Sud   (France)

^d Decibel Therapeutics   (United States)

^e KSQ THERAPEUTICS   (United States)

^f JOSC LLC Consulting   (United States)

^g Sage Therapeutics Inc   (United States)

^h SHIRE   (United States)

ⁱ R and D   (China)

^j VERTEX PHARMACEUTICALS   (United States)

^k Drug Product Development   (United States)

^l AKEBIA THERAPEUTICS   (United States)

more..

Author keywords

2 hydroxyglutarate; AG 120; differentiation therapy; isocitrate dehydrogenase; ivosidenib; mutant IDH1

Indexed keywords

2 HYDROXYGLUTARIC ACID; ARGININE; ISOCITRATE DEHYDROGENASE 1; IVOSIDENIB; MUTANT PROTEIN; PREGNANE X RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG SAFETY; ENZYME ACTIVE SITE; EPIGENETICS; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; REACTION OPTIMIZATION; RECEPTOR UPREGULATION; SOMATIC MUTATION; TUMOR MODEL;

EID: 85045384985     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00421     Document Type: Article

References (18)

1. Dang, L.; Su, S. M. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. Annu. Rev. Biochem. 2017, 86, 305-331, 10.1146/annurev-biochem-061516-044732
2. Dang, L.; White, D. W.; Gross, S.; Bennett, B. D.; Bittinger, M. A.; Driggers, E. M.; Fantin, V. R.; Jang, H. G.; Jin, S.; Keenan, M. C.; Marks, K. M.; Prins, R. M.; Ward, P. S.; Yen, K. E.; Liau, L. M.; Rabinowitz, J. D.; Cantley, L. C.; Thompson, C. B.; Vander Heiden, M. G.; Su, S. M. Cancer-associated IDH1 Mutations Produce 2-Hydroxyglutarate. Nature 2009, 462 (7274), 739-744, 10.1038/nature08617
3. Figueroa, M. E.; Abdel-Wahab, O.; Lu, C.; Ward, P. S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H. F.; Tallman, M. S.; Sun, Z.; Wolniak, K.; Peeters, J. K.; Liu, W.; Choe, S. E.; Fantin, V. R.; Paietta, E.; Lowenberg, B.; Licht, J. D.; Godley, L. A.; Delwel, R.; Valk, P. J.; Thompson, C. B.; Levine, R. L.; Melnick, A. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 2010, 18 (6), 553-567, 10.1016/j.ccr.2010.11.015
4. Lu, C.; Ward, P. S.; Kapoor, G. S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C. R.; Khanin, R.; Figueroa, M. E.; Melnick, A.; Wellen, K. E.; O'Rourke, D. M.; Berger, S. L.; Chan, T. A.; Levine, R. L.; Mellinghoff, I. K.; Thompson, C. B. IDH Mutation Impairs Histone Demethylation and Results in a Block to Cell Differentiation. Nature 2012, 483 (7390), 474-478, 10.1038/nature10860
5. Rohle, D.; Popovici-Muller, J.; Palaskas, N.; Turcan, S.; Grommes, C.; Campos, C.; Tsoi, J.; Clark, O.; Oldrini, B.; Komisopoulou, E.; Kunii, K.; Pedraza, A.; Schalm, S.; Silverman, L.; Miller, A.; Wang, F.; Yang, H.; Chen, Y.; Kernytsky, A.; Rosenblum, M. K.; Liu, W.; Biller, S. A.; Su, S. M.; Brennan, C. W.; Chan, T. A.; Graeber, T. G.; Yen, K. E.; Mellinghoff, I. K. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science 2013, 340 (6132), 626-630, 10.1126/science.1236062
6. Stein, E. M.; DiNardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; DeAngelo, D. J.; Levine, R. L.; Flinn, I. W.; Kantarjian, H. M.; Collins, R.; Patel, M. R.; Frankel, A. E.; Stein, A.; Sekeres, M. A.; Swords, R. T.; Medeiros, B. C.; Willekens, C.; Vyas, P.; Tosolini, A.; Xu, Q.; Knight, R. D.; Yen, K. E.; Agresta, S.; de Botton, S.; Tallman, M. S. Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia. Blood 2017, 130 (6), 722-731, 10.1182/blood-2017-04-779405
7. Stein, E. M.; Yen, K. Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents. Annu. Rev. Canc. Biol. 2017, 1, 379-401, 10.1146/annurev-cancerbio-050216-122051
8. Amatangelo, M. D.; Quek, L.; Shih, A.; Stein, E. M.; Roshal, M.; David, M. D.; Marteyn, B.; Farnoud, N. R.; de Botton, S.; Bernard, O. A.; Wu, B.; Yen, K. E.; Tallman, M. S.; Papaemmanuil, E.; Penard-Lacronique, V.; Thakurta, A.; Vyas, P.; Levine, R. L. Enasidenib Induces Acute Myeloid Leukemia Cell Differentiation to Promote Clinical Response. Blood 2017, 130 (6), 732-741, 10.1182/blood-2017-04-779447
9. Popovici-Muller, J.; Saunders, J. O.; Salituro, F. G.; Travins, J. M.; Yan, S.; Zhao, F.; Gross, S.; Dang, L.; Yen, K. E.; Yang, H.; Straley, K. S.; Jin, S.; Kunii, K.; Fantin, V. R.; Zhang, S.; Pan, Q.; Shi, D.; Biller, S. A.; Su, S. M. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. ACS Med. Chem. Lett. 2012, 3 (10), 850-855, 10.1021/ml300225h
10. Pusch, S.; Krausert, S.; Fischer, V.; Balss, J.; Ott, M.; Schrimpf, D.; Capper, D.; Sahm, F.; Eisel, J.; Beck, A. C.; Jugold, M.; Eichwald, V.; Kaulfuss, S.; Panknin, O.; Rehwinkel, H.; Zimmermann, K.; Hillig, R. C.; Guenther, J.; Toschi, L.; Neuhaus, R.; Haegebart, A.; Hess-Stumpp, H.; Bauser, M.; Wick, W.; Unterberg, A.; Herold-Mende, C.; Platten, M.; von Deimling, A. Pan-mutant IDH1 Inhibitor BAY 1436032 for Effective Treatment of IDH1 Mutant Astrocytoma In Vivo. Acta Neuropathol. 2017, 133 (4), 629-644, 10.1007/s00401-017-1677-y
11. Cho, Y. S.; Levell, J. R.; Liu, G.; Caferro, T.; Sutton, J.; Shafer, C. M.; Costales, A.; Manning, J. R.; Zhao, Q.; Sendzik, M.; Shultz, M.; Chenail, G.; Dooley, J.; Villalba, B.; Farsidjani, A.; Chen, J.; Kulathila, R.; Xie, X.; Dodd, S.; Gould, T.; Liang, G.; Heimbach, T.; Slocum, K.; Firestone, B.; Pu, M.; Pagliarini, R.; Growney, J. D. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med. Chem. Lett. 2017, 8 (10), 1116-1121, 10.1021/acsmedchemlett.7b00342
12. Gao, Y. D.; Olson, S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. Y.; Tang, W.; Hartley, D. P.; Mosley, R. T. Attenuating Pregnane X Receptor (PXR) Activation: A Molecular Modelling Approach. Xenobiotica 2007, 37 (2), 124-138, 10.1080/00498250601050412
13. Fan, B.; Goyal, L.; Lowery, M. A.; Pandya, S. S.; Manyak, E.; Le, K.; Jiang, L.; Auer, J.; Dai, D. Pharmacokinetic/pharmacodynamic (PK/PD) Profile of AG-120 in Patients with IDH1-Mutant Cholangiocarcinoma From a Phase 1 Study of Advanced Solid Tumors. J. Clin. Oncol. 2017, 35 (15 Suppl), Abstract 4082. 10.1200/JCO.2017.35.15-suppl.4082
14. Fan, B.; Le, K.; Manyak, E.; Liu, H.; Prahl, M.; Bowden, C. J.; Biller, S.; Agresta, S.; Yang, H. Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies. Blood 2015, 126 (23), Abstract 1310.
15. DiNardo, C. D.; de Botton, S.; Stein, E. M.; Roboz, G. J.; Mims, A. S.; Pollyea, D. A.; Swords, R. T.; Altman, J. K.; Collins, R. H.; Mannis, G. N.; Uy, G. L.; Donnellan, W.; Pigneux, A.; Fathi, A. T.; Stein, A. S.; Erba, H. P.; Prince, G. T.; Foran, J. M.; Traer, E.; Stuart, R. K.; Arellano, M. L.; Slack, J. L.; Sekeres, M. A.; Yen, K.; Kapsalis, S. M.; Liu, H.; Goldwasser, M.; Agresta, S.; Attar, E. C.; Tallman, M. S.; Stone, R. M.; Kantarjian, H. M. Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. Blood 2017, 130 (Suppl), Abstract 725.
16. Mellinghoff, I. K.; Touat, M.; Maher, E.; de la Fuente, M.; Cloughesy, T. F.; Holdhoff, M.; Cote, G. M.; Burris, H.; Janku, F.; Huang, R.; Young, R. J.; Ellingson, B.; Nimkar, T.; Jiang, L.; Ishii, Y.; Choe, S.; Fan, B.; Steelman, L.; Yen, K.; Bowden, C.; Pandya, S.; Wen, P. Y. AG-120, a First-In-Class Mutant IDH1 Inhibitor in Patients with Recurrent or Progressive IDH1 Mutant Glioma: Updated Results From the Phase 1 Non-Enhancing Glioma Population. Neuro-Oncology 2017, 19 (Suppl 6), vi10, 10.1093/neuonc/nox168.037
17. Lowery, M. A.; Abou-Alfa, G. K.; Burris, H. A.; Janku, F.; Shroff, R. T.; Cleary, J. M.; Azad, N. S.; Goyal, L.; Maher, E. A.; Gore, L.; Hollebecque, A.; Beeram, M.; Trent, J. C.; Jiang, L.; Ishii, Y.; Auer, J.; Gliser, C.; Agresta, S. V.; Pandya, S. S.; Zhu, A. X. Phase I Study of AG-120, an IDH1 Mutant Enzyme Inhibitor: Results From the Cholangiocarcinoma Dose Escalation and Expansion Cohorts. J. Clin. Oncol. 2017, 35 (15 Suppl), 4015, 10.1200/JCO.2017.35.15-suppl.4015
18. DiNardo, C. D.; de Botton, S.; Stein, E. M.; Roboz, G. J.; Swords, R. T.; Pollyea, D. A.; Fathi, A. T.; Collins, R.; Altman, J. K.; Flinn, I. W.; Mannis, G. N.; Mims, A. S.; Foran, J. M.; Pigneux, A.; Prince, G. T.; Uy, G. L.; Tallman, M. S.; Kantarjian, H. M.; Liu, H.; Attar, E. C.; Sacolick, J.; Yen, K.; Hurov, J. B.; Choe, S.; Wu, B.; Stone, R. M. Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. Blood 2016, 128 (22), Abstract 1070.